TGTX Stock Overview
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
TG Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.00|
|52 Week High||US$35.94|
|52 Week Low||US$3.48|
|1 Month Change||-11.77%|
|3 Month Change||14.29%|
|1 Year Change||-81.37%|
|3 Year Change||15.16%|
|5 Year Change||-49.58%|
|Change since IPO||428.05%|
Recent News & Updates
TG Therapeutics: We Are Just Hanging In There
Summary 2022 has been a terrible year for a once-promising TGTX. Maybe the FDA decision on December 28 will help us break even. I don't have any further expectations from TGTX. TG Therapeutics, Inc. (TGTX) is an unfortunate story for investors. Just like with Amarin Corporation plc (AMRN), the investment logic here was sound, however, it was ruined by random events. In Amarin's case, we had one approval, one major label expansion, and then along came Judge Du. In TG's case, we had one small approval, one major new approval on the horizon, and then they were forced to withdraw the first drug from the market. This killed the buzz around the upcoming approval, which, as we always knew, was the big thing. So the stock has ridden itself all the way down to $6, and nothing seems to be able to move it. December 28 is the big day, when the FDA will decide on the NDA of ublituximab in multiple sclerosis. There are numerous reasons why we think this will turn out well; and a few reasons it might not. I gave some stats in an earlier article. The Ultimate trials were run under an agreement with the FDA called the Special Protocol Assessment, which means, essentially, that the FDA agrees to the "scientificality" of the clinical endpoints chosen by the company. So if a trial under an SPA met the clinical endpoint - which it did here - the FDA is bound to approve. In about 1000 such SPAs since 1997, the FDA has rescinded its agreement on just 1% of the time. So there's a 99% chance of approval. That's one big reason for our optimism. Ublituximab has consistently scored below 0.1 for the Annualized Relapse Rate or ARR, a feat that none of the other currently approved drugs - not a single one - has been able to achieve in their pivotal trials. ARR is an important metric for calculating drug efficacy in MS trials. It is defined as the number of relapses of MS occurring during a one-year period. Ublituximab not only beat the comparator drug in the Ultimate trials, but it also beat Roche's (RHHBY) Ocrevus or ocrelizumab, a blockbuster MS drug, on a cross trial basis. I discussed the 1-hour infusion time earlier. While the company in its earnings call states that this is the foremost differentiator, I am not sure I can agree. Ocrevus has had a 2-hour infusion program approved in December 2020, and given the infusion-related AEs seen in Ultimate, I believe not just the infusion time but also the hospital setting itself matters a lot. I think the company needs to focus on other differentiating factors. In an earlier article, I wondered whether the Unity-CLL trial will need to be re-analyzed for ublituximab's contribution to the poor OS data. However, I think that's kind of moot. Ubli's central adverse effect is infection, which occurs because it kills B-cells, like it is supposed to. In the Ultimate trials, there were three deaths, all infection related. However, in Unity, infection was not the issue, at least not the issue that led to the poor OS. Umbralisib has its own P13K-related issues. So I doubt ublituximab will have a problem here, and if this was the cause for the 3-month delay in review. About this delay, in their latest earnings call, the company provided some color: Since this submission, as is customary during a BLA review process, we have continued to respond to additional FDA information requests, none to my knowledge, specifically related to the submission that resulted in the delay. Generally speaking, my team tells me that they believe the process is moving forward as expected.
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
TG Therapeutics (NASDAQ:TGTX) on Thursday said results from its two-part phase 3 trials evaluating its investigational monoclonal antibody ublituximab for the treatment of multiple sclerosis were published in the peer-reviewed New England Journal of Medicine (NEJM). TGTX stock +0.5% to $7.52 in morning trading. Ublituximab, a targeted B-cell therapy, showed significant reductions in risk of relapses, as well as reduction of active or new brain lesions, in the two-part late-stage trial, called ULTIMATE I and II. If approved, the therapy would be given as a 1-hour infusion every 6 months, following the first dose. The U.S. FDA and Europe's drug regulator are currently reviewing marketing applications for ublituximab for the treatment of relapsing forms of multiple sclerosis in adults. The FDA is set to decide on the application by Dec. 28, 2022, TG Therapeutics (TGTX) had previously said.
|TGTX||US Biotechs||US Market|
Return vs Industry: TGTX underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: TGTX underperformed the US Market which returned -23.2% over the past year.
|TGTX Average Weekly Movement||15.0%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: TGTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: TGTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics Fundamentals Summary
|TGTX fundamental statistics|
Is TGTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TGTX income statement (TTM)|
|Cost of Revenue||US$762.00k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.13|
|Net Profit Margin||-4,144.51%|
How did TGTX perform over the long term?See historical performance and comparison
Is TGTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TGTX?
Other financial metrics that can be useful for relative valuation.
|What is TGTX's n/a Ratio?|
Price to Book Ratio vs Peers
How does TGTX's PB Ratio compare to its peers?
|TGTX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
MIRM Mirum Pharmaceuticals
KNSA Kiniksa Pharmaceuticals
TGTX TG Therapeutics
Price-To-Book vs Peers: TGTX is expensive based on its Price-To-Book Ratio (6.3x) compared to the peer average (4.5x).
Price to Earnings Ratio vs Industry
How does TGTX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: TGTX is expensive based on its Price-To-Book Ratio (6.3x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is TGTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||6.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate TGTX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of TGTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TGTX ($6) is trading below our estimate of fair value ($186.19)
Significantly Below Fair Value: TGTX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is TG Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TGTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TGTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TGTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TGTX's revenue (63.1% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: TGTX's revenue (63.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TGTX is forecast to be unprofitable in 3 years.
Discover growth companies
How has TG Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TGTX is currently unprofitable.
Growing Profit Margin: TGTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TGTX is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Accelerating Growth: Unable to compare TGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: TGTX has a negative Return on Equity (-223.58%), as it is currently unprofitable.
Discover strong past performing companies
How is TG Therapeutics's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TGTX's short term assets ($202.6M) exceed its short term liabilities ($43.3M).
Long Term Liabilities: TGTX's short term assets ($202.6M) exceed its long term liabilities ($79.3M).
Debt to Equity History and Analysis
Debt Level: TGTX has more cash than its total debt.
Reducing Debt: TGTX's debt to equity ratio has increased from 0.2% to 53.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TGTX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TGTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is TG Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|TG Therapeutics Dividend Yield vs Market|
|Company (TG Therapeutics)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (TG Therapeutics)||0%|
Notable Dividend: Unable to evaluate TGTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TGTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TGTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TGTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TGTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Weiss (56 yo)
Mr. Michael S. Weiss, Esq., J.D., also known as Mike, has been an Executive Chairman of Mustang Bio Inc. since January 2017 and served as the Interim President and Chief Executive Officer at Mustang Bio In...
CEO Compensation Analysis
|Mike Weiss's Compensation vs TG Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$43m||US$1m|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$32m||US$1m|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$13m||US$637k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$14m||US$656k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$10m||US$525k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$4m||US$375k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$14m||US$325k|
Compensation vs Market: Mike's total compensation ($USD42.67M) is above average for companies of similar size in the US market ($USD4.14M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
Experienced Management: TGTX's management team is seasoned and experienced (7.6 years average tenure).
Experienced Board: TGTX's board of directors are considered experienced (8.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|05 Jan 22||SellUS$1,282,527||Michael Weiss||Individual||68,220||US$19.20|
|05 Jan 22||SellUS$1,622,737||Sean Power||Individual||84,965||US$19.20|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
TG Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: TG Therapeutics, Inc.
- Ticker: TGTX
- Exchange: NasdaqCM
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$811.615m
- Shares outstanding: 135.27m
- Website: https://www.tgtherapeutics.com
Number of Employees
- TG Therapeutics, Inc.
- 2 Gansevoort Street
- 9th Floor
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TGTX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Dec 2011|
|NKB2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2011|
|0VGI||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Dec 2011|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.